Skip to Content

The TruScreen Device

Clinical Performance

Development History

Eliminating Cervical Cancer

The TruScreen Device

Clinical Performance

Development History

Eliminating Cervical Cancer

The TruScreen Device

Clinical Performance

Development History

Eliminating Cervical Cancer

TruScreen Limited Preliminary Consolidated Financial Statements

15 June

Written By

TruScreen Preliminary Results for the Year Ended 31 March 2017

TruScreen Limited NZX Appendix 1 Release

A world without cervical cancer.

Quick links

The TruScreen Device

Markets & Distributors

Contact

info@truscreen.com

TruScreen Group Limited (NZX/ASX: TRU) is a New Zealand and Australian listed medical device company that has developed an AI-enabled device that can detect precancerous and cancerous cervical changes in real-time via optical and electrical measurements of cervical tissue. Unlike many cervical screening devices, that have only triage/adjunct functionality, the TruScreen device is registered as a stand alone primary screening tool.

© 2025 Truscreen Group Ltd. All rights reserved.